Home » BMS’ Colorectal Cancer Drug Gets Accelerated Approval
BMS’ Colorectal Cancer Drug Gets Accelerated Approval
The FDA granted accelerated approval to Bristol-Myers Squibbs’ metastatic colorectal cancer drug Opdivo (nivolumab).
The agency based its decision on data from a single-arm, open-label study of 53 patients with locally determined dMMR or MSI-H metastatic colorectal cancer progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
No trials were conducted for pediatric patients but the accelerated approval applied to patients 12 years and older.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May